Efficacy of various CD19.CAR T-cell products in r/r B-ALL compared with B-NHL
| CD19.CAR T cells in r/r B-ALL . | CD19.CAR T cells in r/r B-NHL . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CAR T-cell product . | Age (y) . | No. of pts . | Efficacy CR (MRD-neg CR) . | Median duration of response . | CAR T-cell product . | Age (y) . | No. of pts . | Efficacy CR (PR) . | Median duration of response . |
| Tisagenlecleucel (Maude, 201841 ) | 3-21 | 75 | 81% MRD-neg CR | Not reached | Tisagenlecleucel (Schuster et al, 20194 ) | 22-76 | 93 | 40% (12%) | Not reached |
| Axicabtagene ciloleucel (Wierda, 201842 ) | 18-69 | 35 | 78% MRD-neg CR | NP | Axicabtagene ciloleucel (Neelapu et al, 20175 ) | 23-76 | 101 | 54% (28%) | 8.1 mo |
| JCAR014 (Turtle, 201643 ) | 20-73 | 29 | 93% (86%) | NP | JCAR014 (Turtle, 201644 ) | 22-70 | 32 | 50% (22%) | NP |
| CD19.CD28ζ (Lee et al, 20152 ) | 1-30 | 21 | 70% (60%) | NP | CD19.CD28ζ (Kochenderfer, 201745 ) | 26-67 | 22 | 55% (18%) | 12.5 mo |
| CD19.CAR T cells in r/r B-ALL . | CD19.CAR T cells in r/r B-NHL . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CAR T-cell product . | Age (y) . | No. of pts . | Efficacy CR (MRD-neg CR) . | Median duration of response . | CAR T-cell product . | Age (y) . | No. of pts . | Efficacy CR (PR) . | Median duration of response . |
| Tisagenlecleucel (Maude, 201841 ) | 3-21 | 75 | 81% MRD-neg CR | Not reached | Tisagenlecleucel (Schuster et al, 20194 ) | 22-76 | 93 | 40% (12%) | Not reached |
| Axicabtagene ciloleucel (Wierda, 201842 ) | 18-69 | 35 | 78% MRD-neg CR | NP | Axicabtagene ciloleucel (Neelapu et al, 20175 ) | 23-76 | 101 | 54% (28%) | 8.1 mo |
| JCAR014 (Turtle, 201643 ) | 20-73 | 29 | 93% (86%) | NP | JCAR014 (Turtle, 201644 ) | 22-70 | 32 | 50% (22%) | NP |
| CD19.CD28ζ (Lee et al, 20152 ) | 1-30 | 21 | 70% (60%) | NP | CD19.CD28ζ (Kochenderfer, 201745 ) | 26-67 | 22 | 55% (18%) | 12.5 mo |
MRD-neg, minimal residual disease–negative, NP, not provided; PR, partial response.